

Cost-effectiveness of Population Screening for BRCA Mutations in Women Compared With Family History–Based Testing

Journal of the National Cancer Institute

107, 380

DOI: [10.1093/jnci/dju380](https://doi.org/10.1093/jnci/dju380)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Is It Time to Offer BRCA1 and BRCA2 Testing to All Jewish Women?. <i>Current Oncology</i> , 2015, 22, 233-236.	0.9	16
3	BRCA1/2 Population Screening: Embracing the Benefits. <i>Current Oncology</i> , 2015, 22, 230-231.	0.9	6
4	Survey on Addressing the Information and Support Needs of Jewish Women at Increased Risk for or Diagnosed with Breast Cancer: The Sharsheret Experience. <i>Healthcare (Switzerland)</i> , 2015, 3, 324-337.	1.0	7
5	Proposed Shift in Screening for Breast Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 525.	3.8	3
6	Imaging surveillance programs for women at high breast cancer risk in Europe: Are women from ethnic minority groups adequately included? (Review). <i>International Journal of Oncology</i> , 2015, 47, 817-839.	1.4	6
7	Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 351-364.	1.6	23
8	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
9	Population-Wide Screening for Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: Too Much of a Good Thing?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3092-3095.	0.8	43
10	Diagnosis of ovarian cancer. <i>BMJ, The</i> , 2015, 351, h4443.	3.0	68
11	Cost-effectiveness of Universal BRCA1/2 Screening. <i>JAMA Oncology</i> , 2015, 1, 1217.	3.4	33
12	Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. <i>Frontiers in Oncology</i> , 2016, 6, 119.	1.3	15
13	Breast Cancer Genetic Counseling: A Surgeon's Perspective. <i>Frontiers in Surgery</i> , 2016, 3, 4.	0.6	11
14	Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. <i>Journal of Medical Genetics</i> , 2016, 53, 472-480.	1.5	42
15	Specifying the ovarian cancer risk threshold of "premenopausal risk-reducing salpingo-oophorectomy" for ovarian cancer prevention: a cost-effectiveness analysis. <i>Journal of Medical Genetics</i> , 2016, 53, 591-599.	1.5	57
16	The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada. <i>Journal of Genetic Counseling</i> , 2016, 25, 1309-1316.	0.9	24
17	The future of clinical cancer genomics. <i>Seminars in Oncology</i> , 2016, 43, 615-622.	0.8	23
18	Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. <i>Genetics in Medicine</i> , 2016, 18, 1171-1180.	1.1	68
19	Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. <i>The Cochrane Library</i> , 2016, , .	1.5	3

#	ARTICLE	IF	CITATIONS
20	Genetic testing and personalized ovarian cancer screening: a survey of public attitudes. <i>BMC Women's Health</i> , 2016, 16, 46.	0.8	29
21	Randomized Noninferiority Trial of Telephone Delivery of <i>BRCA1/2</i> Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2016, 34, 2914-2924.	0.8	91
22	Germline <i>BRCA1/2</i> testing practices in ovarian cancer: Current state and opportunities for new directions. <i>Gynecologic Oncology</i> , 2016, 140, 90-94.	0.6	11
23	Genetic Epidemiology and Public Health: The Evolution From Theory to Technology. <i>American Journal of Epidemiology</i> , 2016, 183, 387-393.	1.6	12
24	Crucial considerations for pipelines to validate circulating biomarkers for breast cancer. <i>Expert Review of Proteomics</i> , 2016, 13, 201-211.	1.3	6
25	Genetic screening for gynecological cancer: where are we heading?. <i>Future Oncology</i> , 2016, 12, 207-220.	1.1	11
26	The hallmarks of premalignant conditions: a molecular basis for cancer prevention. <i>Seminars in Oncology</i> , 2016, 43, 22-35.	0.8	27
27	Population genetic testing for cancer susceptibility: founder mutations to genomes. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 41-54.	12.5	86
28	Hereditary Ovarian Cancer and Risk Reduction. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 31-48.	1.4	40
29	Decision making for breast cancer prevention among women at elevated risk. <i>Breast Cancer Research</i> , 2017, 19, 34.	2.2	64
30	Precision reproductive medicine: multigene panel testing for infertility risk assessment. <i>Journal of Assisted Reproduction and Genetics</i> , 2017, 34, 967-973.	1.2	11
31	Population screening for <i>BRCA1/BRCA2</i> mutations: lessons from qualitative analysis of the screening experience. <i>Genetics in Medicine</i> , 2017, 19, 628-634.	1.1	25
32	Population-Based Study of Attitudes toward <i>BRCA</i> Genetic Testing among Orthodox Jewish Women. <i>Breast Journal</i> , 2017, 23, 333-337.	0.4	13
33	A Cost-Effectiveness Evaluation of Germline <i>BRCA1</i> and <i>BRCA2</i> Testing in UK Women with Ovarian Cancer. <i>Value in Health</i> , 2017, 20, 567-576.	0.1	54
34	A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer. <i>Value in Health</i> , 2017, 20, 547-555.	0.1	40
35	Use of <i>BRCA</i> Mutation Test in the U.S., 2004–2014. <i>American Journal of Preventive Medicine</i> , 2017, 52, 702-709.	1.6	64
36	Genetic testing for gynaecological cancer. <i>Obstetrics, Gynaecology and Reproductive Medicine</i> , 2017, 27, 29-31.	0.1	0
38	Cost-effectiveness of population based <i>BRCA</i> testing with varying Ashkenazi Jewish ancestry. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 578.e1-578.e12.	0.7	63

#	ARTICLE	IF	CITATIONS
39	Experiences from a pilot program bringing BRCA1/2 genetic screening to the. <i>Genetics in Medicine</i> , 2017, 19, 529-536.	1.1	16
40	Community attitudes towards a Jewish community BRCA1/2 testing program. <i>Familial Cancer</i> , 2017, 16, 17-28.	0.9	7
41	Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK. <i>BMJ Open</i> , 2017, 7, e017675.	0.8	16
42	Simulation modeling for stratified breast cancer screening â€” a systematic review of cost and quality of life assumptions. <i>BMC Health Services Research</i> , 2017, 17, 802.	0.9	6
43	BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. <i>ESMO Open</i> , 2018, 3, e000328.	2.0	17
44	Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. <i>Journal of Medical Genetics</i> , 2018, 55, 538-545.	1.5	45
45	Ovarian Cancer Prevention and Screening. <i>Obstetrics and Gynecology</i> , 2018, 131, 909-927.	1.2	176
46	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. <i>Journal of the National Cancer Institute</i> , 2018, 110, 714-725.	3.0	138
47	Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review. <i>Genetics in Medicine</i> , 2018, 20, 1145-1156.	1.1	28
48	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 431.e1-431.e12.	0.7	32
49	Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. <i>Genetics in Medicine</i> , 2018, 20, 985-994.	1.1	76
50	Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 395-406.	1.0	14
51	Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 469-477.	1.1	18
52	Germline BRCA mutation in male carriersâ€”ripe for precision oncology?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 48-56.	2.0	13
53	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	0.8	155
54	Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation. <i>Revista De Saude Publica</i> , 2018, 52, 94.	0.7	9
55	Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach. <i>Public Health Genomics</i> , 2018, 21, 186-196.	0.6	4
56	Population Based Testing for Primary Prevention: A Systematic Review. <i>Cancers</i> , 2018, 10, 424.	1.7	31

#	ARTICLE	IF	CITATIONS
57	TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients. PLoS ONE, 2018, 13, e0209934.	1.1	10
58	Population Testing for High Penetrance Genes: Are We There Yet?. Journal of the National Cancer Institute, 2018, 110, 687-689.	3.0	6
60	Cancer genetics, precision prevention and a call to action. Nature Genetics, 2018, 50, 1212-1218.	9.4	94
61	A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer. Breast Cancer Research and Treatment, 2018, 172, 637-646.	1.1	19
62	Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. Journal of Genetic Counseling, 2018, 27, 1405-1410.	0.9	3
63	Pharmacogenomics and Psychiatric Clinical Care. Journal of Psychosocial Nursing and Mental Health Services, 2018, 56, 22-31.	0.3	4
65	Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model. Familial Cancer, 2019, 18, 381-388.	0.9	8
66	Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer. Journal of Surgical Oncology, 2019, 120, 864-872.	0.8	11
67	Cost-effectiveness of precision medicine: a scoping review. International Journal of Public Health, 2019, 64, 1261-1271.	1.0	55
68	An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Expert Review of Anticancer Therapy, 2019, 19, 787-801.	1.1	16
69	The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Human Mutation, 2019, 40, e1-e23.	1.1	34
70	Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines. Journal of Molecular Diagnostics, 2019, 21, 646-657.	1.2	81
71	Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 784-794.	1.1	23
72	A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 686-689.	1.1	3
73	A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 293-302.	1.1	6
74	Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genetics in Medicine, 2019, 21, 1958-1968.	1.1	63
75	Polygenic risk scoring and prediction of mental health outcomes. Current Opinion in Psychology, 2019, 27, 77-81.	2.5	25
76	Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. Genetics in Medicine, 2019, 21, 913-922.	1.1	45

#	ARTICLE	IF	CITATIONS
77	Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 189-201.	1.0	10
78	Randomised trial of population-based <i>BRCA</i> testing in Ashkenazi Jews: long-term outcomes. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 364-375.	1.1	45
79	Online <i>BRCA1/2</i> screening in the Australian Jewish community: a qualitative study. <i>Journal of Community Genetics</i> , 2020, 11, 291-302.	0.5	11
80	Knowledge and opinions regarding <i>BRCA1</i> and <i>BRCA2</i> genetic testing among primary care physicians. <i>Journal of Genetic Counseling</i> , 2020, 29, 122-130.	0.9	16
81	Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions. <i>Journal of Clinical Oncology</i> , 2020, 38, 332-350.	0.8	25
82	Current Approaches to Germline Cancer Genetic Testing. <i>Annual Review of Medicine</i> , 2020, 71, 85-102.	5.0	12
83	Economic Evaluation of Population-Based <i>BRCA1/BRCA2</i> Mutation Testing across Multiple Countries and Health Systems. <i>Cancers</i> , 2020, 12, 1929.	1.7	49
84	Women's Intentions to Engage in Risk-Reducing Behaviours after Receiving Personal Ovarian Cancer Risk Information: An Experimental Survey Study. <i>Cancers</i> , 2020, 12, 3543.	1.7	5
85	Canadian cost-effectiveness model of <i>BRCA</i> -driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 104-112.	0.2	13
86	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. <i>Cancers</i> , 2020, 12, 1241.	1.7	19
87	Population-based Genetic Testing for Precision Prevention. <i>Cancer Prevention Research</i> , 2020, 13, 643-648.	0.7	20
88	Population-based genetic testing for Women's cancer prevention. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 139-153.	1.4	23
89	Healthcare Utilization and Costs after Receiving a Positive <i>BRCA1/2</i> Result from a Genomic Screening Program. <i>Journal of Personalized Medicine</i> , 2020, 10, 7.	1.1	16
90	Population Screening for Inherited Predisposition to Breast and Ovarian Cancer. <i>Annual Review of Genomics and Human Genetics</i> , 2020, 21, 373-412.	2.5	31
91	A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. <i>Cancer Prevention Research</i> , 2020, 13, 429-442.	0.7	10
92	Genetic counselors' perspectives on population-based screening for <i>BRCA</i> -related hereditary breast and ovarian cancer and Lynch syndrome. <i>Journal of Genetic Counseling</i> , 2021, 30, 158-169.	0.9	8
93	Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis. <i>PLoS ONE</i> , 2021, 16, e0247363.	1.1	14
94	A simple framework to identify optimal cost-effective risk thresholds for a single screen: Comparison to Decision Curve Analysis. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2021, 184, 887.	0.6	3

#	ARTICLE	IF	CITATIONS
95	Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper. <i>BMJ Open</i> , 2021, 11, e041186.	0.8	2
96	Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!. <i>Oncology Reviews</i> , 2021, 15, 544.	0.8	4
97	Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies. <i>European Journal of Health Economics</i> , 2021, 22, 1311-1344.	1.4	18
98	Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 35.	0.6	8
99	Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions. <i>Oncotarget</i> , 2021, 12, 1600-1614.	0.8	14
100	Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 165-175.	1.4	12
101	Population based germline testing for primary cancer prevention. <i>Oncotarget</i> , 2018, 9, 33062-33063.	0.8	4
105	Defining Health-Related Quality of Life in Localized and Advanced Stages of Breast Cancer – the First Step towards Hereditary Cancer Genetic Counseling. <i>Acta Clinica Croatica</i> , 2020, 59, 209-215.	0.1	2
106	Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel. <i>Cancer Prevention Research</i> , 2021, 14, 455-462.	0.7	14
107	A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer. <i>Global & Regional Health Technology Assessment</i> , 2020, 7, 1-8.	0.2	0
108	Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 959-968.	1.1	3
109	Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol. <i>Journal of Personalized Medicine</i> , 2021, 11, 1194.	1.1	1
110	Preventive population genomics: The model of BRCA related cancers. <i>Advances in Genetics</i> , 2021, 108, 1-33.	0.8	1
111	A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders. <i>Genetics in Medicine</i> , 2022, 24, 262-288.	1.1	4
112	Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria. <i>Scientific Reports</i> , 2022, 12, 2507.	1.6	8
113	Population-based screening of Uruguayan Ashkenazi Jews for recurrent BRCA1 and BRCA2 pathogenic sequence variants. <i>Molecular Genetics & Genomic Medicine</i> , 2022, , e1928.	0.6	1
114	Perspectives on Ovarian Cancer 1809 to 2022 and Beyond. <i>Diagnostics</i> , 2022, 12, 791.	1.3	7
115	Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by TP53 p.R337H Carriers. <i>Frontiers in Oncology</i> , 2022, 12, 836937.	1.3	8

#	ARTICLE	IF	CITATIONS
116	Do current family history-based genetic testing guidelines contribute to breast cancer health inequities?. <i>Npj Breast Cancer</i> , 2022, 8, 36.	2.3	9
117	Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. <i>Diagnostics</i> , 2022, 12, 1028.	1.3	3
119	Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 153-160.	1.1	4
120	Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term secondary lifestyle behavioural outcomes. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1970-1980.	1.1	4
121	Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome. <i>Cancers</i> , 2022, 14, 4717.	1.7	1
122	Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12057.	1.2	17
123	From the patient to the population: Use of genomics for population screening. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
124	What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing. <i>Cancer</i> , 2022, 128, 4241-4250.	2.0	4
125	A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. <i>Journal of Medical Economics</i> , 2023, 26, 19-33.	1.0	4
126	Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies. <i>Cancers</i> , 2022, 14, 6113.	1.7	3
127	Cost-Effectiveness of Genetic Testing Strategies for Breast Cancer. , 2023, , 113-126.		0